Crinetics Pharmaceuticals has agreed to be acquired by Vertex Pharmaceuticals in a cash deal that values the endocrine-disease specialist at about $10 billion in equity, or roughly $8.8 billion net of estimated cash acquired. Vertex will pay $85.00 per share. Joele Frank, Wilkinson Brimmer Katcher advised Crinetics.
One medicine sits at the center of the transaction. Crinetics’ Palsonify, known generically as paltusotine, is the first and only once-daily oral therapy for a condition caused by a pituitary tumor that secretes excess growth hormone. The drug won U.S. Food and Drug Administration approval in September 2025 and recently cleared the European Medicines Agency. For patients who have long managed the disease with injections, an oral option changes the daily routine of treatment. Acromegaly is rare, and those who live with it often cycle through monthly injections for years, so a pill taken once a day carries both clinical and commercial weight.
Vertex, which reported $12 billion in sales for 2025, framed the purchase around fit rather than reach. CEO Reshma Kewalramani called Crinetics an excellent match “with its focus on serious diseases in specialty markets with significant unmet need, well-understood causal human biology, and potentially best-in-class medicines that could deliver transformative benefit to patients.”
She sees room to extend the Palsonify launch by drawing on Vertex’s record commercializing medicines for rare genetic diseases, the corner of the market where the company built its name treating cystic fibrosis.
The gap between the two figures attached to the deal is worth a moment. Vertex placed the equity value near $10 billion and the net cost around $8.8 billion, the difference being cash already on Crinetics’ books. Both numbers describe the same agreement; which one a headline uses depends on what it counts.
Boards at both companies approved the transaction unanimously, and the parties expect it to close in the third quarter of 2026. Beyond Palsonify, Crinetics brings a pipeline that includes atumelnant, a candidate in development for congenital adrenal hyperplasia and Cushing’s syndrome. That gives Vertex more than a single marketed product to build on. Vertex has said the two assets together carry peak potential of more than $5 billion in combined annual revenue, the kind of ceiling that helps explain a ten-figure price for a company with one approved drug.
Joele Frank, Wilkinson Brimmer Katcher partners Jamie Moser and Jed Repko, and managing directors Catherine Simon and Fouad Boutros represented Crinetics.
For a buyer known almost entirely for cystic fibrosis, the deal widens the therapeutic map into endocrinology while keeping to a familiar template: acquire a company with a well-understood biological target and a product already reaching patients. Whether that discipline holds as Vertex integrates a second specialty franchise is the question the next several quarters will answer.
